Q3 2022 EPS Estimates for Harmony Biosciences Holdings, Inc. Cut by Analyst (NASDAQ:HRMY)

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMYGet Rating) – Analysts at Oppenheimer dropped their Q3 2022 earnings per share estimates for shares of Harmony Biosciences in a research note issued to investors on Tuesday, August 2nd. Oppenheimer analyst F. Brisebois now anticipates that the company will earn $0.01 per share for the quarter, down from their prior estimate of $0.46. Oppenheimer currently has a “Outperform” rating and a $67.00 target price on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $1.66 per share. Oppenheimer also issued estimates for Harmony Biosciences’ FY2022 earnings at $1.18 EPS and FY2023 earnings at $2.24 EPS.

Harmony Biosciences (NASDAQ:HRMYGet Rating) last posted its quarterly earnings data on Tuesday, August 2nd. The company reported $0.39 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.44 by ($0.05). Harmony Biosciences had a return on equity of 60.12% and a net margin of 15.95%. During the same period in the previous year, the firm earned $0.54 earnings per share.

Other equities research analysts have also recently issued reports about the company. Raymond James increased their target price on Harmony Biosciences from $58.00 to $60.00 and gave the company an “outperform” rating in a report on Wednesday. Cantor Fitzgerald began coverage on Harmony Biosciences in a report on Thursday, April 14th. They set an “overweight” rating and a $63.00 target price for the company. The Goldman Sachs Group cut Harmony Biosciences from a “buy” rating to a “neutral” rating and set a $55.00 target price for the company. in a report on Tuesday, July 12th. Mizuho dropped their target price on Harmony Biosciences from $64.00 to $60.00 and set a “buy” rating for the company in a report on Thursday. Finally, Jefferies Financial Group lowered Harmony Biosciences from a “buy” rating to a “hold” rating and set a $57.00 price target for the company. in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $59.86.

Harmony Biosciences Trading Up 0.3 %

Shares of HRMY stock opened at $52.50 on Friday. The stock has a market capitalization of $3.10 billion, a PE ratio of 55.26 and a beta of 0.33. Harmony Biosciences has a 1-year low of $26.25 and a 1-year high of $57.13. The business has a 50-day moving average of $49.55 and a 200 day moving average of $45.07. The company has a debt-to-equity ratio of 0.77, a current ratio of 4.91 and a quick ratio of 4.88.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Royce & Associates LP increased its position in Harmony Biosciences by 4.8% during the 2nd quarter. Royce & Associates LP now owns 268,197 shares of the company’s stock valued at $13,080,000 after buying an additional 12,390 shares in the last quarter. Envestnet Asset Management Inc. bought a new position in Harmony Biosciences during the 2nd quarter valued at approximately $319,000. Lisanti Capital Growth LLC bought a new position in Harmony Biosciences during the 2nd quarter valued at approximately $14,820,000. New York State Teachers Retirement System increased its position in Harmony Biosciences by 108.0% during the 2nd quarter. New York State Teachers Retirement System now owns 14,462 shares of the company’s stock valued at $705,000 after buying an additional 7,510 shares in the last quarter. Finally, Calamos Advisors LLC bought a new position in Harmony Biosciences during the 2nd quarter valued at approximately $2,881,000. Institutional investors own 75.62% of the company’s stock.

Insider Buying and Selling at Harmony Biosciences

In other Harmony Biosciences news, Director Andreas Wicki sold 12,640 shares of the company’s stock in a transaction that occurred on Thursday, August 4th. The stock was sold at an average price of $52.67, for a total transaction of $665,748.80. Following the completion of the transaction, the director now owns 3,620,124 shares of the company’s stock, valued at approximately $190,671,931.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Jack Nielsen sold 180,838 shares of the stock in a transaction that occurred on Thursday, July 7th. The stock was sold at an average price of $56.01, for a total value of $10,128,736.38. Following the completion of the transaction, the director now owns 3,432,006 shares of the company’s stock, valued at approximately $192,226,656.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Andreas Wicki sold 12,640 shares of the stock in a transaction that occurred on Thursday, August 4th. The stock was sold at an average price of $52.67, for a total value of $665,748.80. Following the completion of the transaction, the director now directly owns 3,620,124 shares of the company’s stock, valued at approximately $190,671,931.08. The disclosure for this sale can be found here. Insiders sold 502,307 shares of company stock valued at $26,998,410 in the last 90 days. Insiders own 34.70% of the company’s stock.

Harmony Biosciences Company Profile

(Get Rating)

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Featured Stories

Earnings History and Estimates for Harmony Biosciences (NASDAQ:HRMY)

Want More Great Investing Ideas?

Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.